Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 39 citing articles:

<p>Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy</p>
Yao Chen, Juan Yang, Shaozhi Fu, et al.
International Journal of Nanomedicine (2020) Vol. Volume 15, pp. 9407-9430
Open Access | Times Cited: 224
The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Josée Golay, Ronald P. Taylor
Antibodies (2020) Vol. 9, Iss. 4, pp. 58-58
Open Access | Times Cited: 77
Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
Zvi Fishelson, Michael Kirschfink
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 69
Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, et al.
JCI Insight (2022) Vol. 7, Iss. 6
Open Access | Times Cited: 29
CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity
Yu Wang, Yajun Yang, Zhu Wang, et al.
Oncology Letters (2017) Vol. 14, Iss. 3, pp. 2961-2969
Open Access | Times Cited: 59
Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles
Esteban Cruz, Veysel Kayser
Cancers (2019) Vol. 11, Iss. 6, pp. 870-870
Open Access | Times Cited: 39
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer
Xiaoyong Fu, Resel Pereira, Chia-Chia Liu, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112821-112821
Open Access | Times Cited: 11
Characterization of the Regulation of CD46 RNA Alternative Splicing
Sze Jing Tang, Shufang Luo, Jia Xin Jessie Ho, et al.
Journal of Biological Chemistry (2016) Vol. 291, Iss. 27, pp. 14311-14323
Open Access | Times Cited: 34
The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer
Qianwen Ouyang, Long Zhang, Yi‐Zhou Jiang, et al.
International Journal of Oncology (2016) Vol. 48, Iss. 5, pp. 2015-2024
Open Access | Times Cited: 34
Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical
Chao Tang, Lan Li, Tong Mo, et al.
Clinical & Translational Oncology (2022) Vol. 24, Iss. 9, pp. 1682-1701
Open Access | Times Cited: 16
Complement system's role in cancer and its therapeutic potential in ovarian cancer
Halin Bareke, Jülide Akbuğa
Scandinavian Journal of Immunology (2018) Vol. 88, Iss. 1
Open Access | Times Cited: 23
The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer
Ping Zhao, Jun Wu, Feiteng Lu, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches
Vitalijs Ovcinnikovs, Karin Dijkman, Gijs G. Zom, et al.
Seminars in Immunology (2024) Vol. 77, pp. 101922-101922
Open Access | Times Cited: 2
New perspectives on complement mediated immunotherapy
Grzegorz Stasiłojć, Anders Österborg, Anna M. Blom, et al.
Cancer Treatment Reviews (2016) Vol. 45, pp. 68-75
Closed Access | Times Cited: 18
Bispecific Complement Engagers for Targeted Complement Activation
Dennis Pedersen, Heidi Gytz, Mikael B. L. Winkler, et al.
The Journal of Immunology (2023) Vol. 211, Iss. 3, pp. 403-413
Closed Access | Times Cited: 6
FHR4‐based immunoconjugates direct complement‐dependent cytotoxicity and phagocytosis towards HER2‐positive cancer cells
Carole Seguin‐Devaux, Jean‐Marc Plesséria, Charlène Verschueren, et al.
Molecular Oncology (2019) Vol. 13, Iss. 12, pp. 2531-2553
Open Access | Times Cited: 17
Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Maryam Sadri, Alireza Najafi, Ali Rahimi, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110470-110470
Closed Access | Times Cited: 5
Downregulation of complement factor H attenuates the stemness of MDA‑MB‑231 breast cancer cells via modulation of the ERK and p38 signaling pathways
Soon Park, Da‐Young Eum, Yunho Jin, et al.
Oncology Letters (2023) Vol. 26, Iss. 6
Open Access | Times Cited: 5
CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma
Flora Cimmino, Marianna Avitabile, Lucia Pezone, et al.
Oncogenesis (2016) Vol. 5, Iss. 4, pp. e212-e212
Open Access | Times Cited: 12
Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations
Ralph E. Parchment, Andrea Regier Voth, James H. Doroshow, et al.
Seminars in Oncology (2016) Vol. 43, Iss. 4, pp. 501-513
Closed Access | Times Cited: 9
Breast Cancer Updates
Selim Sözen, Seyfi Emir
IntechOpen eBooks (2022)
Open Access | Times Cited: 5
Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells
Lucyna Kapka‐Skrzypczak, Sylwia Popek-Marciniec, Krzysztof Sawicki, et al.
Oncology Letters (2016) Vol. 12, Iss. 2, pp. 1507-1512
Open Access | Times Cited: 6
Effect of membrane‑bound complement regulatory proteins on tumor cell sensitivity to complement‑dependent cytolysis triggered by heterologous expression of the α‑gal xenoantigen
Yu Wang, Juan Liao, Yajun Yang, et al.
Oncology Letters (2018)
Open Access | Times Cited: 6
Improvement of Antibody Activity by Controlling Its Dynamics Using the Glycan–Lectin Interaction
Yoshiyuki Manabe, Yuki Iizuka, Ryuku Yamamoto, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 30
Closed Access | Times Cited: 2
Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer
Rebeca E. Montalvo-Castro, Nohemí Salinas-Jazmín
Gaceta Médica de México (2022) Vol. 158, Iss. 3
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top